Biogen plans to buy Sage Therapeutics for $7.22/share, a 30% premium, valuing company at $441.7M.

From Investing.com: 2025-01-10 19:44:47

Biogen plans to acquire Sage Therapeutics for $7.22 per share, a 30% premium, valuing the company at $441.7 million. Biogen already owns 10.2% of Sage. Biogen has seen slow sales for its Alzheimer’s drug, while Sage abandoned a drug development after trial failures and shifted focus to postpartum depression drug Zurzuvae. Sage also discontinued development of a neurological disorder drug.



Read more at Investing.com: Biogen proposes to buy remaining stake in Sage in $442 million deal By Reuters